Extracellular lipid loading augments hypoxic paracrine signaling and promotes glioma angiogenesis and macrophage infiltration.


Journal

Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647

Informations de publication

Date de publication:
07 06 2019
Historique:
received: 04 04 2019
accepted: 13 05 2019
entrez: 9 6 2019
pubmed: 9 6 2019
medline: 18 12 2019
Statut: epublish

Résumé

Primary brain tumors, in particular glioblastoma (GBM), remain among the most challenging cancers. Like most malignant tumors, GBM is characterized by hypoxic stress that triggers paracrine, adaptive responses, such as angiogenesis and macrophage recruitment, rescuing cancer cells from metabolic catastrophe and conventional oncological treatments. The unmet need of strategies to efficiently target tumor "stressness" represents a strong clinical motivation to better understand the underlying mechanisms of stress adaptation. Here, we have investigated how lipid loading may be involved in the paracrine crosstalk between cancer cells and the stromal compartment of the hypoxic tumor microenvironment. Regions from patient GBM tumors with or without the lipid loaded phenotype were isolated by laser capture microdissection and subjected to comparative gene expression analysis in parallel with cultured GBM cells with or without lipid loading. The potential involvement of extracellular lipids in the paracrine crosstalk with stromal cells was studied by immunoprofiling of the secretome and functional studies in vitro as well as in various orthotopic GBM mouse models, including hyperlipidemic ApoE-/- mice. Statistical analyses of quantitative experimental methodologies were performed using unpaired Student's T test. For survival analyses of mouse experiments, log-rank test was used, whereas Kaplan-Meier was performed to analyze patient survival. We show that the lipid loaded niche of GBM patient tumors exhibits an amplified hypoxic response and that the acquisition of extracellular lipids by GBM cells can reinforce paracrine activation of stromal cells and immune cells. At the functional level, we show that lipid loading augments the secretion of e.g. VEGF and HGF, and may potentiate the cross-activation of endothelial cells and macrophages. In line with these data, in vivo studies suggest that combined local tumor lipid loading and systemic hyperlipidemia of ApoE-/- mice receiving a high fat diet induces tumor vascularization and macrophage recruitment, and was shown to significantly decrease animal survival. Together, these data identify extracellular lipid loading as a potentially targetable modulator of the paracrine adaptive response in the hypoxic tumor niche and suggest the contribution of the distinct lipid loaded phenotype in shaping the glioma microenvironment.

Sections du résumé

BACKGROUND
Primary brain tumors, in particular glioblastoma (GBM), remain among the most challenging cancers. Like most malignant tumors, GBM is characterized by hypoxic stress that triggers paracrine, adaptive responses, such as angiogenesis and macrophage recruitment, rescuing cancer cells from metabolic catastrophe and conventional oncological treatments. The unmet need of strategies to efficiently target tumor "stressness" represents a strong clinical motivation to better understand the underlying mechanisms of stress adaptation. Here, we have investigated how lipid loading may be involved in the paracrine crosstalk between cancer cells and the stromal compartment of the hypoxic tumor microenvironment.
METHODS
Regions from patient GBM tumors with or without the lipid loaded phenotype were isolated by laser capture microdissection and subjected to comparative gene expression analysis in parallel with cultured GBM cells with or without lipid loading. The potential involvement of extracellular lipids in the paracrine crosstalk with stromal cells was studied by immunoprofiling of the secretome and functional studies in vitro as well as in various orthotopic GBM mouse models, including hyperlipidemic ApoE-/- mice. Statistical analyses of quantitative experimental methodologies were performed using unpaired Student's T test. For survival analyses of mouse experiments, log-rank test was used, whereas Kaplan-Meier was performed to analyze patient survival.
RESULTS
We show that the lipid loaded niche of GBM patient tumors exhibits an amplified hypoxic response and that the acquisition of extracellular lipids by GBM cells can reinforce paracrine activation of stromal cells and immune cells. At the functional level, we show that lipid loading augments the secretion of e.g. VEGF and HGF, and may potentiate the cross-activation of endothelial cells and macrophages. In line with these data, in vivo studies suggest that combined local tumor lipid loading and systemic hyperlipidemia of ApoE-/- mice receiving a high fat diet induces tumor vascularization and macrophage recruitment, and was shown to significantly decrease animal survival.
CONCLUSIONS
Together, these data identify extracellular lipid loading as a potentially targetable modulator of the paracrine adaptive response in the hypoxic tumor niche and suggest the contribution of the distinct lipid loaded phenotype in shaping the glioma microenvironment.

Identifiants

pubmed: 31174567
doi: 10.1186/s13046-019-1228-6
pii: 10.1186/s13046-019-1228-6
pmc: PMC6556032
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

241

Subventions

Organisme : Vetenskapsrådet
ID : 2018- 654 02562
Organisme : Vetenskapsrådet
ID : K2011-52X-21737-01-3
Organisme : Cancerfonden
ID : 2017/664
Organisme : Cancerfonden
ID : 2016/365
Organisme : Barncancerfonden
ID : PR2015-0078
Organisme : Fru Berta Kamprad Foundation
ID : N/A
Organisme : Skåne University Hospital donation funds
ID : N/A
Organisme : Governmental funding of clinical research within the national health services, ALF
ID : N/A
Organisme : Viveca Jeppsson
ID : N/A

Références

Semin Cell Dev Biol. 1999 Feb;10(1):51-8
pubmed: 10355028
Nat Rev Mol Cell Biol. 2001 Aug;2(8):599-609
pubmed: 11483993
Arterioscler Thromb Vasc Biol. 2001 Oct;21(10):1567-70
pubmed: 11597927
Proc Natl Acad Sci U S A. 1992 May 15;89(10):4471-5
pubmed: 1584779
Oncogene. 2007 Aug 2;26(35):5070-7
pubmed: 17310988
Cancer Res. 2008 Feb 15;68(4):1003-11
pubmed: 18281474
Br J Cancer. 2008 Jul 8;99(1):185-90
pubmed: 18560401
Nat Rev Cancer. 2008 Nov;8(11):865-73
pubmed: 18923434
Semin Cancer Biol. 2009 Feb;19(1):12-6
pubmed: 19114105
Curr Opin Lipidol. 2009 Jun;20(3):197-205
pubmed: 19395962
Cancer Res. 2009 Nov 1;69(21):8349-55
pubmed: 19808953
PLoS Genet. 2010 Jan 29;6(1):e1000832
pubmed: 20126413
PLoS One. 2011 Feb 16;6(2):e16957
pubmed: 21359215
NMR Biomed. 2011 Jul;24(6):592-611
pubmed: 21538631
Nature. 2012 Nov 15;491(7424):364-73
pubmed: 23151579
Nat Med. 2013 Oct;19(10):1264-72
pubmed: 24056773
JAMA. 2013 Nov 6;310(17):1842-50
pubmed: 24193082
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Cell Metab. 2014 Mar 4;19(3):393-406
pubmed: 24606897
Trends Cell Biol. 2014 Aug;24(8):472-8
pubmed: 24985940
Nat Commun. 2014 Aug 22;5:4684
pubmed: 25147954
Cell Rep. 2014 Oct 9;9(1):349-365
pubmed: 25263561
Hum Pathol. 2015 Feb;46(2):231-8
pubmed: 25476123
Int J Cancer. 2015 Jul 15;137(2):278-88
pubmed: 25477239
J Cell Biol. 2015 Apr 13;209(1):13-22
pubmed: 25869663
Neurology. 2015 Oct 13;85(15):1342-50
pubmed: 26377253
Nat Neurosci. 2016 Jan;19(1):20-7
pubmed: 26713745
Eur J Clin Nutr. 2016 Jul;70(7):757-65
pubmed: 26908425
JCI Insight. 2016;1(2):
pubmed: 26973881
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Cancer Res. 2016 Aug 15;76(16):4828-40
pubmed: 27199348
Biochim Biophys Acta. 2016 Aug;1866(1):76-86
pubmed: 27343712
Neuro Oncol. 2017 Jan;19(1):43-54
pubmed: 27365097
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Mol Cell Proteomics. 2017 Mar;16(3):502-511
pubmed: 28111361
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Cancer Res. 2017 May 1;77(9):2266-2278
pubmed: 28235764
Cancer Cell. 2017 Mar 13;31(3):326-341
pubmed: 28292436
Front Cell Dev Biol. 2017 Apr 26;5:43
pubmed: 28491867
Nat Cell Biol. 2018 Jul;20(7):823-835
pubmed: 29915361
Nat Rev Neurol. 2018 Aug;14(8):482-495
pubmed: 29985475
Cell Rep. 2018 Sep 4;24(10):2596-2605.e5
pubmed: 30184495
EMBO J. 2018 Dec 3;37(23):
pubmed: 30322894
Clin Cancer Res. 2019 May 15;25(10):3115-3127
pubmed: 30679164
Cancer Res. 1970 Sep;30(9):2394-400
pubmed: 5475483
J Neurosurg. 1996 Mar;84(3):449-58
pubmed: 8609557

Auteurs

Svenja Offer (S)

Department of Clinical Sciences Lund, Section of Oncology and Pathology, Lund University, Barngatan 4, SE-221 85, Lund, Sweden.
Center for Translational Cancer Research, Technical University of Munich, Munich, Germany.

Julien A Menard (JA)

Department of Clinical Sciences Lund, Section of Oncology and Pathology, Lund University, Barngatan 4, SE-221 85, Lund, Sweden.

Julio Enríquez Pérez (JE)

Department of Clinical Sciences Lund, Section of Neurosurgery, Lund University, Lund, Sweden.

Kelin G de Oliveira (KG)

Department of Clinical Sciences Lund, Section of Oncology and Pathology, Lund University, Barngatan 4, SE-221 85, Lund, Sweden.

Vineesh Indira Chandran (V)

Department of Clinical Sciences Lund, Section of Oncology and Pathology, Lund University, Barngatan 4, SE-221 85, Lund, Sweden.

Maria C Johansson (MC)

Department of Clinical Sciences Lund, Section of Oncology and Pathology, Lund University, Barngatan 4, SE-221 85, Lund, Sweden.

Anna Bång-Rudenstam (A)

Department of Clinical Sciences Lund, Section of Oncology and Pathology, Lund University, Barngatan 4, SE-221 85, Lund, Sweden.

Peter Siesjö (P)

Department of Clinical Sciences Lund, Section of Neurosurgery, Lund University, Lund, Sweden.
Department of Neurosurgery, Skåne University Hospital, Lund, Sweden.

Anna Ebbesson (A)

Department of Clinical Sciences Lund, Section of Oncology and Pathology, Lund University, Barngatan 4, SE-221 85, Lund, Sweden.

Ingrid Hedenfalk (I)

Department of Clinical Sciences Lund, Section of Oncology and Pathology, Lund University, Barngatan 4, SE-221 85, Lund, Sweden.

Pia C Sundgren (PC)

Department of Clinical Sciences, Lund, Section of Diagnostic Radiology, Lund University, Lund, Sweden.
Department of Medical Imaging and Function, Skåne University Hospital, Lund, Sweden.

Anna Darabi (A)

Department of Clinical Sciences Lund, Section of Neurosurgery, Lund University, Lund, Sweden.

Mattias Belting (M)

Department of Clinical Sciences Lund, Section of Oncology and Pathology, Lund University, Barngatan 4, SE-221 85, Lund, Sweden. Mattias.Belting@med.lu.se.
Department of Hematology, Oncology and Radiophysics, Skåne University Hospital, Lund, Sweden. Mattias.Belting@med.lu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH